Serotype 1 viruses modified by backpassage or insertional mutagenesis: Approaching the threshold of vaccine efficacy in Marek's disease

Avian Diseases

Volumn 48, Issue 4, 2004, Pages 768-782

  Witter, R L ^a   Kreager, K S ^b  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b Hy Line International   (United States)

Author keywords

Attenuation; Backpassage; Insertional mutagenesis; Marek's disease; Vaccine

Indexed keywords

ANIMALIA; AVES; GALLUS GALLUS; UNIDENTIFIED RETROVIRUS;

EID: 11244255658     PISSN: 00052086     EISSN: None     Source Type: Journal    
DOI: 10.1637/7203-050304R     Document Type: Article

References (40)

1. Burgoyne, G. H., and R. L. Witter. Effect of passively transferred immunoglobulins on Marek's disease. Avian Dis. 17:824-837. 1973.
2. Calnek, B. W., and M. W. Smith. Vaccination against Marek's disease with cell-free turkey herpesvirus: interference by maternal antibody. Avian Dis. 16:954-957. 1972.
3. Churchill, A. E., R. C. Chubb, and W. Baxendale. The attenuation, with loss of oncogenicity, of the herpes-type virus of Marek's disease (strain HPRS-16) on passage in cell culture. J. Gen. Virol. 4:557-564. 1969.
4. Churchill, A. E., L. N. Payne, and R. C. Chubb. Immunization against Marek's disease using a live attenuated virus. Nature 221:744-747. 1969.
5. Cui, Z. Z., Z. Zhang, A. J. Qin, and L. F. Lee. Analyzing the H19- and T65-epitopes in 38 kd phosphorylated protein of Marek's disease viruses and comparing chicken immunological reactions to viruses point-mutated in the epitopes. Sci. China C Life Sci. 47:82-91. 2004.
6. de Boer, G. F., J. E. Groenendal, H. L. Oei, and J. M. A. Pol. Protective efficacy of clones of Marek's disease virus strain CVI-988. In: Proc. International Symposium on Marek's Disease. B. W. Calnek and J.L. Spencer, eds. American Association of Avian Pathologists, Kennett Square, PA. pp. 531-544. 1985.
7. de Boer, G. F., J. M. A. Pol, and S. H. M. Jeurissen. Marek's disease vaccination strategies using vaccines made from three avian herpesvirus serotypes. In: Advances in Marek's disease research. S. Kato, T. Horiuchi, T. Mikami, and K. Hirai, eds. Japanese Association on Marek's Disease, Osaka, Japan. pp. 405-413. 1989.
8. de Boer, G. F., J. M. A. Pol, and H. L. Oei. Biological characteristics of Marek's disease vaccine CVI-988 clone C1. Vet. Q. 9:16-28. 1987.
9. Games, P. A. An improved t table for simultaneous control of g contrasts. J. Am. Stat. Assoc. 72:531-534. 1977.
10. Gimeno, I. M., R. L. Witter, H. D. Hunt, S. M. Reddy, and U. Neumann. Differential attenuation of the induction by Marek's disease virus of transient paralysis and persistent neurological disease: a model for pathogenesis studies. Avian Pathol. 30:397-409. 2001.
11. Gimeno, I. M., R. L. Witter, H. D. Hunt, S. M. Reddy, and W. M. Reed. Biocharacteristics shared by highly protective vaccines against Marek's disease. Avian Pathol. 33:59-68. 2004.
12. Isfort, R. J., D. Jones, R. G. Kost, R. L. Witter, and H. J. Kung. Retrovirus insertion into herpesvirus in vitro and in vivo. Proc. Natl. Acad. Sci. U S A 89:991-995. 1992.
13. Jones, D., P. Brunovskis, R. Witter, and H. J. Kung. Retroviral insertional activation in a herpesvirus: transcriptional activation of Us genes by an integrated long terminal repeat in a Marek's disease virus clone. J. Virol. 70:2460-2467. 1996.
14. Karpathy, R. C., G. A. Firth, and G. A. Tannock. Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus. Aust. Vet. J. 80:39-44. 2002.
15. Karpathy, R. C., G. A. Firth, and G. A. Tannock. Field evaluations of safety and efficacy of an Australian Marek's disease vaccine. Aust. Vet. J. 81:222-225. 2003.
16. Kreager, K. Chicken industry strategies for control of tumor virus infections. Poult. Sci. 77:1213-1216. 1998.
17. Lee, L. F., X. Liu, and R. L. Witter. Monoclonal antibodies with specificity for three different serotypes of Marek's disease viruses in chickens. J. Immunol. 130:1003-1006. 1983.
18. Nazerian, K. Attenuation of Marek's disease virus and study of its properties in two different cell cultures. J. Natl. Cancer Inst. 44:1257-1267. 1970.
19. Okazaki, W., H. G. Purchase, and B. R. Burmester. Protection against Marek's disease by vaccination with a herpesvirus of turkeys. Avian Dis. 14:413-429. 1970.
20. Purchase, H. G., and G. H. Burgoyne. Immunofluorescence in the study of Marek's disease: detection of antibody. Am. J. Vet. Res. 31:117-123. 1970.
21. Rispens, B. H., H. van Vloten, N. Mastenbroek, H. J. L. Maas, and K. A. Schat. Control of Marek's disease in the Netherlands, I: isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Dis. 16:108-125. 1972.
22. Schat, K. A., B. W. Calnek, and J. Fabricant. Characterization of two highly oncogenic strains of Marek's disease virus. Avian Pathol. 11:593-605. 1982.
23. Settnes, O. P. Experiment on vaccination against Marek's disease with a Danish live attenuated MD-virus (CPRL II HP). Norsk. Vet. Tidsskr. 24:592-595. 1972.
24. Sevoian, M., D. M. Chamberlain, and F. T. Counter. Avian lymphomatosis, I: experimental reproduction of the neural and visceral forms. Vet. Med. 57:500-501. 1962.
25. Spencer, J. L., A. A. Grunder, A. Robertson, and G. W. Speckmann. Attenuated Marek's disease herpesvirus: protection conferred on strains of chickens varying in genetic resistance. Avian Dis. 16:94-107. 1972.
26. Steel, R. G. D., and J. H. Torrie. Principles and procedures of statistics. McGraw-Hill Book Company, Inc., New York. 1960.
27. Stephens, E. A., R. L. Witter, L. F. Lee, J. M. Sharma, K. Nazerian, and B. M. Longenecker. Characteristics of JMV Marek's disease tumor: a nonproductively infected transplantable cell lacking in rescuable virus. J. Natl. Cancer Inst. 57:865-874. 1976.
28. Witter, R. L. Protection by attenuated and polyvalent vaccines against highly virulent strains of Marek's disease virus. Avian Pathol. 11:49-62. 1982.
29. Witter, R. L. Characteristics of Marek's disease viruses isolated from vaccinated commercial chicken flocks: association of viral pathotype with lymphoma frequency. Avian Dis. 27:113-132. 1983.
30. Witter, R. L. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: comparative efficacy. Avian Dis. 31:752-765. 1987.
31. Witter, R. L. Attenuated revenant serotype 1 Marek's disease viruses: safety and protective efficacy. Avian Dis. 35:877-891. 1991.
32. Witter, R. L. Safety and comparative efficacy of the CVI988/Rispens vaccine strain. In: Proc. 4th International Symposium on Marek's Disease, 19th World's Poultry Congress. World's Poultry Science Association, Amsterdam, the Netherlands. pp. 315-319. 1992.
33. Witter, R. L. Increased virulence of Marek's disease virus field isolates. Avian Dis. 41:149-163. 1997.
34. Witter, R. L. Protective efficacy of Marek's disease vaccines. In: Current topics in microbiology and immunology. K. Hirai, ed. Springer-Verlag, Berlin, Germany. pp. 58-90. 2001.
35. Witter, R. L. Induction of strong protection by vaccination with partially attenuated serotype 1 Marek's disease viruses. Avian Dis. 46:925-937. 2002.
36. Witter, R. L., L. F. Lee, and A. M. Fadly. Characteristics of CVI988/Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek's disease virus. Avian Dis. 39:269-284. 1995.
37. Witter, R. L., D. Li, D. Jones, L. F. Lee, and H. J. Kung. Retroviral insertional mutagenesis of a herpesvirus: a Marek's disease virus mutant attenuated for oncogenicity but not for immunosuppression or in vivo replication. Avian Dis. 41:407-421. 1997.
38. Witter, R. L., K. Nazerian, H. G. Purchase, and G. H. Burgoyne. Isolation from turkeys of a cell-associated herpesvirus antigenically related to Marek's disease virus. Am. J. Vet. Res. 31:525-538. 1970.
39. Witter, R. L., J. M. Sharma, and A. M. Fadly. Pathogenicity of variant Marek's disease virus isolants in vaccinated and unvaccinated chickens. Avian Dis. 24:210-232. 1980.
40. Zanella A., G. Bertoldini, and N. Mambelli. Attenuation of the pathogenicity of Marek's disease virus. Atti. Soc. Ital. Sci. Vet. 24:622-624. 1970.